Senescence-accelerated mice prone 8 (SAMP8) in male as a spontaneous osteoarthritis model

Yohei Sanada1,2, Yasunari Ikuta2, Chenyang Ding2, Masahiro Shinohara3, Dilimulati Yimiti2, Hiroyuki Ishitobi1,2, Keita Nagira4, Minjung Lee5, Takayuki Akimoto5, Sachi Shibata6, Masakazu Ishikawa2, Tomoyuki Nakasa2, Kiminori Matsumbara6, Martin K. Lotz7, Nobuo Adachi3 and Shigeru Miyaki1,2*

Abstract

Background: Animal models of spontaneous osteoarthritis (OA) are sparse and not well characterized. The purpose of the present study is to examine OA-related changes and mechanisms in senescence-accelerated mouse prone 8 (SAMP8) that displays a phenotype of accelerated aging.

Methods: Knees of male SAMP8 and SAM-resistant 1 (SAMR1) mice as control from 6 to 33 weeks of age were evaluated by histological grading systems for joint tissues (cartilage, meniscus, synovium, and subchondral bone), and µCT analysis. Gene expression patterns in articular cartilage were analyzed by real-time PCR. Immunohistochemistry was performed for OA-related factors, senescence markers, and apoptosis.

Results: Starting at 14 weeks of age, SAMP8 exhibited mild OA-like changes such as proteoglycan loss and cartilage fibrillation. From 18 to 33 weeks of age, SAMP8 progressed to partial or full-thickness defects with exposure of subchondral bone on the medial tibia and exhibited synovitis. Histological scoring indicated significantly more severe OA in SAMP8 compared with SAMR1 from 14 weeks [median (interquartile range): SAMR1: 0.89 (0.56–1.81) vs SAMP8: 1.78 (1.35–4.62)] to 33 weeks of age [SAMR1: 1.67 (1.61–1.04) vs SAMP8: 13.03 (12.26–13.57)]. Subchondral bone sclerosis in the medial tibia, bone mineral density (BMD) loss of femoral metaphysis, and meniscus degeneration occurred much earlier than the onset of cartilage degeneration in SAMP8 at 14 weeks of age.

Conclusions: SAMP8 are a spontaneous OA model that is useful for investigating the pathogenesis of primary OA and evaluating therapeutic interventions.

Keywords: Osteoarthritis, Aging, Mouse models, Subchondral bone, Meniscus

Introduction

Osteoarthritis (OA), the most common joint disease, is characterized by joint pain and decreased joint function and caused by various risk factors such as aging, traumatic injury, and obesity. The disease process is associated with changes in all joint tissues, including cartilage, subchondral bone, trabecular bone, synovium, menisci, and ligaments [1]. The mechanisms that mediate the effect of age on OA have not been elucidated completely. Thus, pharmacological approaches for OA prevention or disease-modification are presently not available. Although most in vivo OA studies use secondary OA model via injury, such as destabilization of the medial meniscus (DMM) with transection of ligaments [2], aging is one of the most important OA risk factors.
These models are useful for studying post-traumatic OA but may not be a valid approach for studying mechanisms and treatments of spontaneous aging-related OA. Thus, the understanding of primary OA pathogenesis requires animal models with spontaneous OA-like changes, which are biochemically and histologically similar to human OA.

Spontaneous OA in mice develops much more slowly than in induced OA models. In C57BL/6J OA-prone mice, OA-like changes only become detectable at 12–18 months [3–6]. Thus far, the STR/ort mouse have been established as the only model of primary or spontaneous OA in mice [7, 8]. These mice develop severe lesions occurring by about 15 months in the majority of animals [8]. Senescence-accelerated mice (SAM) are derived from AKR/J breeding colonies, and many sublines of SAM-prone (SAMP) and SAM-resistant (SAMR) mice were developed by selective breeding [9, 10]. SAMP show characteristics of rapid aging and reduced lifespan with a relatively strain-specific phenotype. Among the strains, SAMP8 exhibits aging-related diseases such as neurodegenerative disorders including age-related deteriorations in memory and learning ability, and sarcopenia [10, 11]. However, while other and our groups reported OA-like changes including subchondral bone sclerosis in SAMP8 [12, 13], details about the temporal development of OA, and the mechanisms of OA and the suitability of SAMP8 for preclinical drug testing have not been investigated.

The purpose of the present study is to examine OA-related changes and mechanisms in SAMP8 that displays a phenotype of accelerated aging.

**Materials and methods**

**Senescence-accelerated mice (SAM)**

SAMP8 and SAMR1 at 3 weeks of age were obtained from Japan SLC (Shizuoka, Japan), and only male mice were used in this study as only male mice are commercially available in Japan. A total of 115 SAMR1 and 115 SAMP8 were obtained by the vendor. For the aging study, a total of 90 mice each for SAMR1 and SAMP8 were evaluated in histopathological assessments (SAMR1 n = 10; SAMP8 n = 10 at 6, 9, 11, 14, 18, 28, and 33 weeks of age; SAMR1 n = 20; SAMP8 n = 20 at 23 weeks of age). Furthermore, SAMR1 and SAMP8 at 4 weeks of age (n = 15 for each strain) were used for in vitro studies. All mice were housed in groups of three to five per cage (S 143 mm × 293 mm × H148mm) with a sterilized beta-chip bedding and maintained at 23 ± 1 °C with a 12-h light/dark cycle and acidified water and complete commercial pelleted food ad libitum. All animal experiments were performed according to protocols approved by the Hiroshima University Animal Care and Use Committee.

**Histopathological assessments**

Knee, hip, and ankle joints from each mouse were embedded intact in paraffin after fixation in 4% paraformaldehyde phosphate buffer solution (PBS) for 48 h at 4 °C and decalcification in K-CX (FALMA, Japan) for 6 h at room temperature. Paraffin-embedded knee joints were sectioned at 4.5 μm in the coronal plane through the central weight-bearing region of the anterior and posterior femorotibial joint. Hip and ankle joints were sectioned in the sagittal plane. Three different sections per joint were stained with Safranin O (MUTO PURE CHEMICALS, Tokyo, Japan) and Fast Green (Sigma-Aldrich, USA). Histological assessments were performed on each section, and the average scores from three different sections were used for statistical analysis. Three different researchers were blinded while performing all scorings. In this study, we applied separate scoring systems for articular cartilage, meniscus, subchondral bone, and synovium. Damage of articular cartilage (maximum 24 points per knee joint section; 6 points for each quadrant of the medial and lateral femoral/tibial cartilage) was evaluated using the OARSI scoring system [14]. The criteria for determining OA severity were decided by highest score the four quadrants can reach (Mild OA: 0–3; Moderate OA: 4 to 6; Severe OA: 4 to 6). Subchondral bone changes, meniscus degradation, and the severity of synovitis were evaluated according to previously described histopathological scoring systems [13, 15, 16] using the left knee joints.

**Microcomputed tomography (µCT) analysis**

Mouse lower limb was collected from SAMR1 and SAMP8 at 4, 6, 9, and 23 weeks of age and was kept in...
Fig. 1 (See legend on previous page.)
apoptosis TUNEL Kit direct: MBL, USA) according to the manufacturer’s instructions. Nuclei were stained by 4′,6-diamidino-2-phenylindole (DAPI).

**Isolation of mouse articular cartilage and culture of mouse articular chondrocytes**

Articular cartilage tissues for gene expression analysis were isolated from knee joints of mice at 4 weeks of age under a microscope. For chondrocyte isolation, cartilage was resected from the femoral heads of SAMR1 and SAMP8 at 4 weeks of age and digested with 3.5 mg/ml collagenase Type 2 (Worthington, Lakewood, NJ, USA) in Dulbecco’s modified Eagle’s medium (DMEM) (FUJIFILM Wako, Japan) for 1.5 h at 37 °C. Primary chondrocytes were seeded on a 12-well plate with DMEM with 10% fetal bovine serum and 1% penicillin/streptomycin and cultured for 7–10 days. Then, the chondrocytes (passage 1) with or without IL-1β (1 ng/ml, 24 h) were used in the present experiments.

**Quantitative real-time PCR**

Total RNA was extracted from articular cartilage tissues and cultured chondrocytes using Isogen reagent (Nippon gene, Tokyo, Japan) and RNA purification kit (Direct-zol RNA microprep, Zymo Research, California, USA). Complementary DNA (cDNA) was synthesized with a Reverse Transcription system (iScript supermix, BioRad, California, USA) according to the manufacturer’s protocol. Quantitative polymerase chain reaction (PCR) was performed with the TaqMan Gene Expression Assay probes (Table S7) (Thermo Fisher Scientific). Gapdh was used as the internal control to normalize the sample differences. Relative expression was calculated using the ΔΔCt values, and results were expressed as $2^{-\Delta \Delta Ct}$.

**Measurement of glycosaminoglycan release from cartilage explants**

Femoral head cartilages (femoral cap) were harvested from 4-week-old SAMR1 and SAMP8 mice and weighed. The amount of the released glycosaminoglycan into the conditioned medium was measured using the Blyscan Glycosaminoglycan assay kit (Biocolor, UK) as previously described [13].

**Cytokine analysis in serum**

Mouse serum was collected from abdominal vena cava in SAMR1 (n = 4) and SAMP8 (n = 4) at 9 weeks of age. Measurement of IL-6 in serum was carried out using Milliplex MAP technology. Multiplex Assay kit (MILLIPLYEX, Merk Millipore, USA) was obtained, and the procedure was performed following the manufacturer’s instruction.

**Immunohistochemical analysis**

Slides were pretreated with antigen-retrieval reagent (Immunoactive; Matsunami Glass Ind, Osaka, Japan) at 60 °C for 16 h, followed by blocking with 10% normal horse serum for 30 min. Then, sections were immunostained with anti-P16INK4a antibody (abcam, ab54210; 0.1 µg/mL), anti-ADAMTS-5 antibody (Gene Tex, GTX100332, 10 µg/mL), and anti-MMP13 antibody (Thermo Fisher Scientific, MA5-14,328, 20 µg/ml) diluted in Can Get Signal immunostaining solution (TOYOBO, Tokyo, Japan) using Vectastain Elite ABC-HRP kit and DAB substrate kit. Mouse IgG1 kappa (Thermo Fisher Scientific, 14–4731-82), and mouse IgG2b kappa (14–4714-82), and rabbit IgG (14–4616-82) were used as isotype control antibodies for negative controls (Fig. S5).

**TUNEL staining**

TUNEL staining was completed using an in situ detection kit for programmed cell death detection (MEBSTAIN 70% EtOH after fixation in 4% paraformaldehyde phosphate buffer solution (PBS) for 48 h at 4 °C. Analysis by μCT was performed in the epiphysis of the tibias and the metaphysis of the distal femur as we previously described [13].

**Figure 2**

SAMR8 exhibit spontaneous osteoarthritis-like pathology in knee cartilage with aging. A Safranin O staining of the knee joint in SAMR1 and SAMP8 at 6 to 33 weeks of age (SAMR1, n = 10; SAMP8, n = 10 at 6, 9, 11, 14, 18, 28, 33 weeks and SAMR1, n = 20; SAMP8, n = 20 at 23 weeks). B Histopathologic scores (individual scores of left and right knee joints in SAMR1 and SAMP8 at 6 to 33 weeks of age). OARSI scores of entire knee joint were significantly increased in SAMP8 from 14 weeks of age. C OARSI scores of medial and lateral tibial/femoral cartilage of the left and right knee in the individual mice at 14 to 23 weeks of age in SAMP8. Round dots represent left knees and triangle dots represent right knees. The colors differentiate the individual mice in each time point. Scoring data represented as median with 95% confidence interval and were compared between SAMR1 and SAMP8 in aging analysis by Mann–Whitney U test at each time point. Comparison of right and left knees of SAMP8 mice were performed using Wilcoxon signed-rank test at each time point. The p-values ($P < 0.05$, $P < 0.01$) were corrected using the Holm’s method for multiple comparison correction.
Fig. 2 (See legend on previous page.)
described [17]. After normalized by femoral caps’ weight, the data are expressed as fold differences compared with the amount of glycosaminoglycan into the culture medium with the average of from control SAMR1 strain set to 1.

Statistical analysis
In a pilot study, our comparison of the 23-week-old OARSI score between the 23-week-old SAMR1 group (n = 5) and the SAMP8 group (n = 5) for checking sample size showed an effect size of 2.5 by power analysis using G*power (version 3.1.9.2) (SAMR1: 1.62 ± 0.12, SAMP8: 7.54 ± 3.32). Using this effect size, we calculated the sample size (the power of 0.8 and a significance level of 0.05) and found that at least 6 animals were required in each group. To account for potential dropouts and increase power, the number of animals was increased to 10 in each group (only 23-week-old mice are n = 20 in each group). Thus, we evaluated SAMR1 and SAMP8 as follows SAMR1 n = 10; SAMP8 n = 10 at 6, 9, 11, 14, 18, 28, and 33 weeks of age. For the 23-week time point, we allocated 20 mice per strain to establish as reasonable point for OA evaluation because SAMP8 reliably exhibited OA-like pathologic changes in all joint tissues (cartilage, subchondral bone, meniscus, and synovium). Actual measurement value data are presented as mean ± standard deviation (S.D). Comparison of mean values was performed using Welch’s t test. The p-values were corrected using the Holm-Sidak method for multiple comparison (GraphPad Prism9). Data of body weight was analyzed by two-way factorial ANOVA. Scoring data were compared between SAMR1 vs SAMP8 in aging analysis with Mann–Whitney U test at each time point. The p-values were corrected by using Holm’s method for multiple comparison (GraphPad Prism9). Kendall’s tau-b partial correlation coefficient was used to examine the correlation between the data of OARSI, meniscus, synovial, and subchondral bone scoring. Differences were considered statistically significant at *P < 0.05 and **P < 0.01.

Results
Pathological changes in knee joint tissues with aging
SAMP8 and SAMR1 at 4 weeks of age showed no difference in overall appearance. However, the body weight of SAMP8 was significantly lower than in SAMR1 from 6 weeks of age (Fig. 1A, B). Abnormalities in neither the cellularity of the growth plate (proliferative zone and type X Collagen positive-hypertrophic zone) and articular cartilage nor the structure and shape of the knee joints and their menisci were observed in SAMP8 at 4 weeks of age (Fig. 1C–F). However, the density of chondrocytes was significantly higher in the medial tibial plateau of SAMP8 than that of SAMR1 (Fig. 1F). These findings indicate normal joint development, postnatal growth, and maturation in SAMP8. No mice died by 33 weeks of age in this study.

To investigate whether SAMP8 exhibit an early onset of OA-like changes in cartilage, both knee joints from SAMP8 and SAMR1 were evaluated starting at 6 weeks of age. From 6 to 9 weeks of age, SAMP8 and SAMR1 showed intact articular cartilage and similar proteoglycan staining (Fig. 2A). Starting at 11 weeks of age, SAMP8 mice showed reduced Safranin O staining especially in the medial tibial plateau, indicating proteoglycan loss, a roughened articular surface, and fibrillations that were not associated with synovial hyperplasia, compared with normal tissue appearance in SAMR1 at the same age. Medial menisci degeneration and chondrophyte formation at the margin of the medial tibia was observed in SAMP8. At 18 to 33 weeks of age, SAMP8 exhibited partial or full-thickness cartilage defects with exposure of subchondral bone on the medial tibial plateau with menisci degeneration, synovial hyperplasia and osteophytes in all cases (Fig. 2A). None of these changes were observed in age-matched SAMR1 (Fig. 2A). The individual OARSI scores of all knee joints (left and right knee joints) indicated a significant increase in OA severity compared with SAMR1 at 14 weeks (median (interquartile range), SAMR1 vs SAMP8) [Left: 0.89 (0.56–1.07) vs 1.78 (1.35–4.62), Right: 0.28 (0.24–0.53) vs 1.21 (0.74–1.36)], 18 weeks [Left: 0.94 (0.74–1.14) vs 10.58 (1.94–12.35), Right: 1.03 (0.46–1.21) vs 4.86 (1.88–9.81)], 23 weeks [Left: 1.11 (0.63–1.40) vs 10.24 (3.11–13.13), Right: 1.11 (0.67–1.67) vs 9.22 (3.36–12.15)], 28 weeks...
Fig. 3 (See legend on previous page.)
depigmentation, and chondrification, with joint inflammation. In SAMP8, the histological changes such as rupture, mucoid degeneration, and chondrocyte hypertrophy in articular cartilage has been characterized as a pathological change of OA and inhibiting chondrocyte hypertrophy has been considered as a target for OA treatment [18–20]. The hypertrophic chondrocyte marker type X Collagen was widely expressed from the deep layer to the surface layer of articular cartilage on the medial tibia in SAMP8 from 6 weeks of age (Fig. 5A). Type X Collagen in SAMR1 was only expressed in the deep layer of the bone marrow (BM) at 9 weeks of age (Fig. 2A). Subchondral bone scores using our recently established scoring system, which were at the same level at 4 weeks [13] showed significant differences in medial tibia between SAMP8 and SAMR1 at 6 to 33 weeks (Fig. 4A, Table S4). The mice evaluated with μCT analysis in the epiphysis of the medial tibias and the metaphysis of the distal femur. Indeed, calcium accumulation and BMD (BV/TV, %), trabecular number (Tb.N, 1/mm), and trabecular thickness (Tb.Th, μm) in the medial tibial plateau were significantly higher in SAMP8 compared to SAMR1 at 9 weeks of age (Fig. 4D, E). Trabecular separation (Tb.Sp, μm) was significantly increased in SAMP8 compared to SAMR1 from 9 weeks of age (Fig. 4E). These results indicated that sclerosis was increased in the epiphysis of the medial tibias, while bone density was decreased in the metaphysis of the distal femur in SAMP8.

OA-related markers in blood and articular cartilage of SAMP8

To examine inflammatory condition in SAMP8, inflammatory cytokine in serum was measured. However, IL-6 levels were low in both SAMR1 and SAMP8 (mean values 50.8 pg/ml and 40.0 pg/ml, respectively) at 9 weeks of age before the onset of cartilage damage (data not shown).

We focused on the events in articular cartilage that occur at 4 to 11 weeks of age before the onset of macroscopic and histological cartilage degradation. Chondrocyte hypertrophy in articular cartilage has been characterized as a pathological change of OA and inhibiting chondrocyte hypertrophy has been considered as a target for OA treatment [18–20]. The hypertrophic chondrocyte marker type X Collagen was widely expressed from the deep layer to the surface layer of articular cartilage on the medial tibia in SAMP8 from 6 weeks of age (Fig. 5A). Type X Collagen in SAMR1 was only expressed in the deep layer of the bone marrow (BM) at 9 weeks of age (Fig. 2A).
Fig. 4 (See legend on previous page.)
in the deep layer of articular cartilage (Fig. 5A). However, the expression pattern of type II Collagen in SAMP8 was similar with SAMR1 from 4 to 14 weeks of age (Fig. S2A).

Chondrocyte apoptosis and senescence have been detected in OA cartilage and play an important role in OA pathogenesis [21–23]. From 6 to 11 weeks of age before the onset of cartilage damage, TUNEL-positive cells were increased with age and were mainly localized in the middle to deep zone of medial articular cartilage (Fig. 5B). However, there were no significant differences in articular cartilage and menisci between SAMR1 and SAMP8 (Fig. 5B). The numbers of cells positive for p16INK4a, a marker of senescent or dysfunctional chondrocytes [22–26], were significantly increased in articular cartilage of SAMP8 from 6 weeks of age. In menisci, there were significant differences at 11 weeks of age (Fig. 5C). ADAMTS-5 and MMP-13, which are key enzymes in cartilage degradation, were also significantly increased in articular cartilage of SAMP8 compared with SAMR1 at 11 weeks of age (Fig. 5D). Cells expressing these markers were significantly abundant in the medial side than in the lateral side, consistent with the severity of OA (Fig. S4). We also examined the hip and ankle joints in SAMR1 and SAMP8. Although SAMP8 exhibited severe OA in knee joints at 23 weeks of age, cartilage degradation in hip and ankle joint of SAMP8 was not exhibited (Fig. 6A). There was thus no association between knee OA and OA in hip or/and ankle joints in SAMP8 (Fig. 6A). However, cartilage degradation was observed in the tarsometatarsal joint in both SAMP8 and SAMR1 at 23 weeks of age (Fig. S3A). Furthermore, although type X Collagen and p16INK4a-positive senescent cells were detected, SAMP8 did not exhibit severe OA in hip and ankle joints at 23 weeks (Fig. 6B–E) and 52 weeks of age (Fig. S3B).

Gene expression in knee articular cartilage of SAMP8
To determine whether cells in cartilage of SAMP8 mice have intrinsic changes or defects that lead to early-onset OA, we analyzed gene expression patterns and in vitro functions of chondrocytes and articular cartilage from mice at 4 weeks when there are no OA-like histological changes detectable in cartilage. The expression of OA- or senescence-related genes in articular cartilage tissue was not significantly different between SAMR1 and SAMP8 (Fig. 7A). Cdkn2a and senescence-associated secretory phenotype (SASP) factor IL-6 were undetected in articular cartilage. Cultured articular chondrocytes showed that basal levels or IL-1β induced changes of Adamts5 was significantly increased in SAMP8, while Col2a1, Acan, and Mmp13 were not different between SAMR1 and SAMP8 (Fig. 7B). To further evaluate the phenotype of articular chondrocytes from SAMP8, we quantified glycosaminoglycan release from mouse femoral head cartilage explants from SAMR1 and SAMP8 at 4 weeks of age. IL-1β significantly increased proteoglycan release, but there was no significant difference between SAMR1 and SAMP8 (Fig. 7C).

Relationship of knee joint tissue changes in SAMP8
Finally, we analyzed the correlation of pathological changes between joint tissues (articular cartilage, meniscus, synovium, and subchondral bone) of 14–33-week-old SAMP8 mice (Table S5). There were correlations between synovitis and cartilage damage (r = 0.8827, p < 0.0001), meniscus degeneration and cartilage damage in medial compartment (r = 0.8310, p < 0.0001), and subchondral bone sclerosis and cartilage damage (r = 0.5702, p < 0.0001). These results indicated that the cartilage damage in SAMP8 is associated with the pathologic changes of knee joint tissues as typical OA pathology.

Discussion
OA, an aging-related disease, develops slowly over a long period of time. Thus, in most mouse strains, OA-like structural changes with severe cartilage damage are slow to progress and are not detectable until around 15–22 months of age [3–6]. In addition, there are variations in the incidence and severity of OA within and among mouse strains [2, 27, 28]. Although the STR/Ort mouse is the most widely used model of spontaneous OA and has been featured in over 80 studies [8], the present study shows that in SAMP8 mice, OA development is less variable, and progression is more rapid so that experiments using SAMP8 can be performed on a compressed timescale. Therefore, male SAMP8 is a mouse OA model that is useful for investigating the pathogenesis of primary OA as whole joint disease and for evaluating therapeutic interventions.
Fig. 5 (See legend on previous page.)
Fig. 6 Pathological changes in ankle and hip joints in SAMP8 with aging. A Safranin O staining of the knee, hip and ankle joints in SAMR1 and SAMP8 at 23 weeks of age. B, C Immunohistochemistry using anti-type X Collagen on hip and ankle joints from SAMR1 and SAMP8 at 23 weeks of age. D, E Immunohistochemistry using anti-p16INK4a antibodies on hip and ankle joints from SAMR1 and SAMP8 at 23 weeks of age (ankle and hip: n = 5 for each strain). All data represented as mean ± S.D. Comparison of mean values was performed using the Welch’s t test; *P < 0.05 versus SAMR1.
Although the reasons why SAMP8 display accelerated aging and various disease are still unknown, different combinations of mutations in disease-causing genes may be responsible for the various phenotypes of SAMP strains [29]. SAMP8 develops various aging-related phenotypes such as disruption of autonomic nervous function and circadian rhythm [30–32], neurodegenerative disorders [10], and sarcopenia [11]. However, osteopenia (9-week-old) and OA (14-week-old) occurred much earlier than the development of those diseases. Thus, clarifying the relationship between systemic changes originating from the changes of bone-cartilage may open new insight in aging-related diseases (Fig. 8, Table S5, S6).

Chondrocyte hypertrophy and senescent cells increased at 6 weeks before the onset of cartilage degradation at 14 weeks of age. Increased numbers of hypertrophic chondrocytes in articular cartilage have been observed in OA development, and inhibition of hypertrophy has been shown to reduce the severity of OA [18–20]. Age-related diseases have been characterized by the accumulation of senescent cells in various tissues including cartilage and are associated with age-related pathogenesis [24, 33–36]. According to another study, p16INK4a-positive senescent cells increase in articular cartilage with aging, but p16INK4a-positive cells are not essential for SASP production and are not involved in the development of OA [26]. Although p16INK4a is recognized as a senescent cell marker, relation between accelerated-aging phenotype and p16INK4a-positive senescent cells in SAMP8 has not been characterized yet. In the present study, although many chondrocytes in SAMP8 at 4 weeks of age did not express the senescence marker p16INK4a, the rate of p16INK4a-positive chondrocytes in SAMP8 was increased with aging than in SAMR1. However, p16INK4a was also detected in chondrocytes of the lateral tibial plateau, ankle, and hip joint of SAMP8 which showed less cartilage degeneration than the medial compartment of knee joints at 23 weeks of age. Furthermore, ankle and hip joints expressed p16INK4a but did not exhibit OA-like cartilage defects even at 52 weeks of age (Fig. S3A). Thus, abnormal expression of type X Collagen and p16INK4a-positive chondrocytes in the articular cartilage might not be an essential trigger in the development and progression of OA in SAMP8.

OA is whole joint disease [37], and lesion formation and degeneration of the menisci and cruciate ligaments contribute to the development and progression of OA [38, 39]. In our study, pathological changes of the meniscus in SAMP8 were observed before cartilage degeneration, whereas pathological changes of the cruciate ligament and synovium were observed in knee joints with cartilage degeneration after 14 weeks of age. Thus, the degeneration of cruciate ligaments, and synovitis, are subsequent to cartilage damage and these are likely not to be the major initiator of OA in SAMP8. Subchondral bone sclerosis and BMD loss of femoral metaphysis in SAMP8 were pathological changes that occur at 6 to 9 weeks before the onset of cartilage degradation at 14 weeks of age. The subchondral bone and articular cartilage act as a functional unit in the joint. Subchondral bone sclerosis in OA joints, although often considered secondary, occurs at an early phase of the OA process, and is closely associated with changes to the cartilage [37, 40–42]. Moreover, various subchondral bone-targeting therapeutic agents such as bisphosphonates have potential in OA treatment [40, 43]. Subchondral bone sclerosis in the medial tibia and BMD loss in the metaphysis of the distal femur should be investigated as targets for OA treatment. The functions of BM including bone remodeling and BMSCs in SAMP8 might be reduced with aging. Indeed, cultured BMSCs which were isolated from BM of SAMP8 at 6 months of age were positive for the senescence marker p16INK4a [12]. Although the increasing adiposity and inflammatory cytokines in BM with aging are associated with abnormal bone remodeling [44], adiposity formation was not observed in BM of SAMP8 at 6 to 14 weeks of age. Transplantation of normal young BM into SAMP6 can normalize the BM microenvironment, with the imbalance between bone formation and resorption observed in the osteoporosis-prone SAMP6 mice being ameliorated [45, 46]. However, it is still not understood whether resident skeletal stem cells can contribute to maintenance of articular cartilage [47]. Thus, it might be interesting to determine whether BM transplants can rescue the development of OA in SAMP8. Primary abnormalities in subchondral bone may be a trigger for OA in SAMP8. However, we should further examine the causes of mechanical stress, because we have not

---

**Fig. 7** Gene expression of articular cartilage tissue and cultured chondrocytes in SAMP8. **A** The expression of OA-related genes in articular cartilage tissues from knee joint of SAMR1 and SAMP8 (n = 5 for each strain) at 4 weeks of age. **B** Articular chondrocytes were isolated from the femoral heads of SAMR1 and SAMP8 at 4 weeks of age. The expression of OA-related genes in SAMR1 and SAMP8 chondrocytes with or without IL-1β (1 ng/ml) for 24 h (n = 3 each group). **C** Femoral head cartilage explants from SAMR1 and SAMP8 (n = 6 each group) cultured with or without IL-1β (5 ng/ml) for 72 h. Proteoglycan release into the conditioned medium from cartilage was assayed as the concentration of glycosaminoglycan (GAG) and presented as fold changes to the average of SAMR1 (IL-1). All data represented as mean ± S.D. Comparison of mean values was performed using Welch’s t test. The p-values (P < 0.05, ***P < 0.01) were corrected using the Holm-Sidak method for multiple comparison correction. ns: not significant.
Fig. 7 (See legend on previous page.)
reached a conclusion as to why only the knee joint and the medial compartment shows accelerated subchondral bone change and cartilage degeneration. Further elucidating whether the sequential pathological changes in different joint tissues are inter-connected or independent is important for OA pathogenesis. C57BL6/J mice develop OA earlier and more severe in male compared with female mice [48]. Although the present study evaluated male SAMP8 only, we should further examine whether the severity of OA in SAMP8 depends on sex. In addition, the locomotor activity of SAMP8 was similar to that of SAMR1 at 20 weeks of age [31]. The relationship between OA severity and pain should be evaluated by combination of various new tools such as gait analysis based on motion capture system using marker less using AI technology [49], although it is difficult to evaluate pain in mouse OA model.

Together, our study indicates that SAMP8 is a spontaneous and early-onset OA mouse model that is useful for evaluating OA pathogenesis. SAMP8 exhibited severe OA with the pathologic changes of knee joint tissues. A better understanding of the genes, molecules, and processes involved in the OA pathogenesis of SAMP8 will therefore contribute significantly to the identification of new preventative, protective, and therapeutic approaches for primary OA.

**Abbreviations**

OA: Osteoarthritis; SAMP8: Senescence-accelerated mouse prone 8; SAMR1: Senescence-accelerated mouse-resistant 1; BMD: Bone mineral density; DAPI: 4',6-Diamidino-2-phenylindole; BM: Bone marrow; SASP: Senescence-associated secretory phenotype.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13075-022-02916-5.

- **Additional file 1:** Fig. S1. Incidence of aging-related spontaneous osteoarthritis development in knees of SAMP8 at 23 weeks of age.
- **Additional file 2:** Fig. S2. Histology of whole knee joint in SAMR1 and SAMP8.
- **Additional file 3:** Fig. S3. Hip and ankle joints of SAMP8 with aging.
- **Additional file 4:** Fig. S4. ADAMTS-5 and MMP-13-positive in medial and lateral compartment of the knee from SAMR1 and SAMP8.
- **Additional file 5:** Fig. S5. Isotype control Images of all Antibodies used in Immunohistochemistry.
- **Additional file 6:** Supplementary materials and methods.
- **Additional file 7:** Table S1. OARSI score.
- **Additional file 8:** Table S2. Meniscus score.
- **Additional file 9:** Table S3. Synovitis score.
- **Additional file 10:** Table S4. Subchondral bone score.
- **Additional file 11:** Table S5.
- **Additional file 12:** Table S6.
- **Additional file 13:** Table S7.
Acknowledgements

We thank T. Miyata, E. Ueda, DVM, M. A. Saito, and Y. Takagi for excellent technical support, and M. Miyaki, DVM. Ph.D. for statistical analysis. A part of this work was carried out at the Research Center for Life Science, National Science Center for Basic Research and Development, Hiroshima University.

Authors’ contributions

S.M and Y.S contributed to the conception and design of the study. Y.S, Y.L, C.D, M.S, D.Y, H.I, K.N, S.S, M.L, and T.A performed the experiments. Y.S, C.D, Y.I, M.S, T.N, M.I, K.M, M.L, and N.A, and S.M contribute to the analysis and interpretation of data. Y.S, C.D, and S.M contributed to draft manuscript. All authors read and approved the submitted final manuscript.

Funding

This research was supported by MEXT/JSPS KAKENHI for Grant-in-Aid for Scientific Research (B) Grant 15H04959 (SM), 18KT0018 (MS), the Promotion of Joint International Research Grant 15K03038 (SM), Mitsui Sumitomo Insurance Welfare Foundation (SM), Suzukien Memorial Foundation (SM), and NIH grant AG059418 (ML). The study sponsors had no role in the study design, collection, analysis, and interpretation of data; the writing of the manuscript; or the decision to submit the manuscript for publication.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on request.

Declarations

Ethics approval and consent to participate

All animal experiments were performed according to protocols approved by the institutional Animal Care and Use Committees at Hiroshima University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Medical Center for Translational and Clinical Research, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan. 2 Department of Orthopaedic Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 3 Department of Rehabilitation for the Movement Functions, National Rehabilitation Center for Persons With Disabilities, Saitama, Japan. 4 Department of Orthopaedic Surgery, Tottori University, Tottori, Japan. 5 Faculty of Sport Sciences, Waseda University, Saitama, Japan. 6 Department of Human Life Science Education, Graduate School of Education, Hiroshima University, Higashi-Hiroshima, Japan. 7 Department of Molecular Medicine, Scripps Research, La Jolla, San Diego, CA, USA.

Received: 17 May 2022 Accepted: 24 September 2022 Published online: 18 October 2022

References

1. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(8):1697–707.
2. Bapat S, Hubbard D, Munjal A, Hunter M, Fulzele S. Pros and cons of mouse models for studying osteoarthritis. Clin Transl Med. 2018;7(1):36.
3. Miyaki S, Saito T, Inoue A, Otsuki S, Ito Y, Yokoyama S, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010;24(11):1173–85.
4. Takada T, Miyaki S, Itohiti H, Hiroi Y, Nakaza T, Igarashi K, et al. Bach1 deficiency reduces severity of osteoarthritis through upregulation of heme oxygenase-1. Arthritis Res Th. 2015;17:285.
5. Sumiyoshi N, Itohiti H, Miyaki S, Miyado K, Adachi N, Ohchi M. The role of tetraspan CD9 in osteoarthritis using three different mouse models. Biomed Res. 2016;37(5):283–91.
6. Chang SH, Mori D, Kobayashi H, Mori Y, Nakamoto H, Okada K, et al. Excessive mechanical loading promotes osteoarthritis through the gremlin-1–NF-kappaB pathway. Nat Commun. 2019;10(1):1442.
7. Das-Gupta EP, Lyons TJ, Hoyland JA, Lawton DM, Freemont AJ. New histological observations in spontaneously developing osteoarthritis in the STR/OR mouse questioning its acceptability as a model of human osteoarthritis. Int J Exp Pathol. 1993;74(6):627–34.
8. Staines KA, Poulet B, Wentworth DN, Pitsillides AA. The STR/or mouse model of spontaneous osteoarthritis - an update. Osteoarthritis Cartilage. 2017;25(6):802–8.
9. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol Aging. 1999;20(2):105–10.
10. Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res. 2009;34(4):639–59.
11. Guo AR, Leung KS, Sui PM, Qin JH, Chow SK, Qin L, et al. Muscle mass, structural and functional investigations of senescence-accelerated mouse P8 (SAMP8). Exp Anim. 2015;64(4):425–33.
12. Malaise O, Tachikart Y, Constantines D, Mummme M, Ferreina-Lopez R, Noack S, et al. Mesenchymal stem cell senescence alleviates their intrinsic and seno-suppressive paracrine properties contributing to osteoarthritis development. Aging (Albany NY). 2019;11(20):9128–46.
13. Nagira K, Ikuta Y, Shinohara M, Sanada Y, Omoto T, Kanaya H, et al. Histological scoring system for subchondral bone changes in murine models of joint aging and osteoarthritis. Sci Rep. 2020;10(1):10077.
14. Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage. 2010;18(Suppl 3):S17-23.
15. Kwok J, Onuma H, Olmer M, Lotz MK, Grogan SP, DLima DD. Histopathological analyses of murine menisci: implications for joint aging and osteoarthritis. Osteoarthritis Cartilage. 2016;24(4):709–18.
16. Krenn Y, Morawietz L, Haupl T, Neidel J, Petersen I, Konig A. Grading of chronic synovitis—a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract. 2002;198(3):317–25.
17. Ishiobi H, Sanada Y, Kato Y, Ikuta Y, Shibata S, Yamazaki S, et al. Carnosic acid attenuates cartilage degeneration through induction of heme oxygenase-1 in human articular chondrocytes. Eur J Pharmacol. 2018;830:1–8.
18. Yahara Y, Takemori H, Okada M, Kosi A, Yamashita A, Kobayashi T, et al. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice by inhibiting Silk3. Nat Commun. 2016;7:10959.
19. Saito T, Fukui A, Mabuchi A, Ikeda T, Yano F, Ohba T, et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. Nat Med. 2010;16(6):678–86.
20. Rim YA, Nam Y, Ju JH. The role of chondrocyte hypertrophy and senescence in osteoarthritis initiation and progression. Int J Mol Sci. 2020;21(7):2358.
21. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(7):412–20.
22. McCulloch K, Litherland GJ, Rai TS. Cellular senescence in osteoarthritis pathology. Aging Cell. 2017;16(2):210–8.
23. Hou A, Chen P, Tang H, Meng H, Cheng X, Wang Y, et al. Cellular senescence in osteoarthritis and anti-aging strategies. Mech Ageing Dev. 2018;175:83–7.
24. Jeon OH, Kim C, Laberge RM, Demaria M, Rathod S, Vassero AP, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23(6):775–81.
25. Sessions GA, Copp ME, Liu JY, Sinkler MA, D’Costa S, Diekmann BO. Controlled induction and targeted elimination of p16(Ink4a)-expressing chondrocytes in cartilage explant culture. Faseb J. 2019;33(11):12364–73.
26. Diekmann BO, Sessions GA, Collins JA, Knecht AK, Strum SL, Mirtin MK, et al. Expression of p16(InK) (4a) is a biomarker of chondrocyte aging but does not cause osteoarthritis. Aging Cell. 2018;17(4):e12771.
27. Lampropoulou-Adamidou K, Lelovas P, Karadimas EV, Liakou C, Triantafillopoulos IK, Donatas I, et al. Useful animal models for the research of osteoarthritis. Eur J Orthop Surg Traumatol. 2014;24(4S):263–71.
28. Lapveteläinen T, Hyttinen M, Lindblom J, Länsiö TK, Siironen R, Li SW, et al. More knee joint osteoarthritis (OA) in mice after inactivation of one
allele of type II procollagen gene but less OA after lifelong voluntary wheel running exercise. Osteoarthritis Cartilage. 2001;9(2):152–60.

29. Tanisawa K, Mikami E, Fukui N, Honda Y, Honda S, Ohsawa I, et al. Exome sequencing of senescence-accelerated mice (SAM) reveals deleterious mutations in degenerative disease-causing genes. BMC Genomics. 2013;14:248.

30. Pang KC, Miller JP, Fortress A, McAuley JD. Age-related disruptions of circadian rhythm and memory in the senescence-accelerated mouse (SAMPA): Age (Dordr). 2006,28(3):283–96.

31. Chikamoto A, Sekizawa SI, Tochihai R, Kuwahara M. Early attenuation of autonomic nervous function in senescence accelerated mouse-prone 8 (SAMPA). Exp Anim. 2019;68(4):S1–7.

32. Allison DB, Ren G, Peli-Garcia RA, Mia S, McGinnis GR, Davis J, et al. Diurnal, metabolic and thermogenic alterations in a murine model of accelerated aging. Chronobiol Int. 2020;37(8):1119–39.

33. Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23(9):1072–9.

34. Hwang HS, Kim HA. Chondrocyte apoptosis in the pathogenesis of osteoarthritis. Int J Mol Sci. 2015;16(11):26035–54.

35. Charlier E, Relic B, Deroyer C, Malaise O, Neuville S, Collee J, et al. Insights on molecular mechanisms of chondrocytes death in osteoarthritides. Int J Mol Sci. 2016;17(12):2146.

36. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, et al. Naturally occurring p16(ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184–9.

37. Goldring SR, Goldring MB. Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk. Nat Rev Rheumatol. 2016;12(11):632–44.

38. Swamy N, Wadhwa V, Bajaj G, Chhabra A, Pandey T. Medial meniscal extrusion: detection, evaluation and clinical implications. Eur J Radiol. 2018;102:115–24.

39. Hasegawa A, Otsuki S, Pauli C, Miyaki S, Patil S, Steklov N, et al. Anterior cruciate ligament changes in the human knee joint in aging and osteoarthritis. Arthritis Rheum. 2012;64(3):696–704.

40. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704–12.

41. Muraoka T, Hagino H, Okano T, Enokida M, Teshima R. Role of subchondral bone in osteoarthritis development: a comparative study of two strains of guinea pigs with and without spontaneously occurring osteoarthritis. Arthritis Rheum. 2007;56(10):3366–344.

42. Huang H, Skelly JD, Ayers DC, Song J. Age-dependent changes in the articular cartilage and subchondral bone of C57BL/6 mice after surgical destabilization of medial meniscus. Sci Rep. 2017;7:42294.

43. Khorasani MS, Diko S, Hsia AW, Anderson MJ, Genetos DC, Haudenschild DR, et al. Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res Ther. 2015;17:30.

44. Rharass T, Lucas S. MECHANISMS IN ENDOCRINOLOGY: Bone marrow adiposity and bone, a bad romance? Eur J Endocrinol. 2018;179(6):R165–R2.

45. Ichikawa N, Inaba M, Kushida T, Esami T, Takahara K, Inaba K, et al. Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells. Stem Cells. 2002;20(6):542–51.

46. Takada K, Inaba M, Ichikawa N, Ueda Y, Taira M, Baba S, et al. Treatment of senile osteoporosis in SAMP6 mice by intra-bone marrow injection of allogeneic bone marrow cells. Stem Cells. 2006;24(2):399–405.

47. Ambrosi TH, Longaker MT, Chan CKF. A revised perspective of skeletal stem cell biology. Front Cell Dev Biol. 2019;7:189.

48. van Osch GJ, van der Kraam PM, Vitters EL, Blankenvoort L, van den Berg WB. Induction of osteoarthritis by intra-articular injection of collagenase in mice. Strain and sex related differences. Osteoarthritis Cartilage. 1993;1(3):171–7.

49. Omoto Y, Yimiti D, Sanada Y, Toriyama M, Ding C, Hayashi Y, et al. Tendon-specific dicer-deficient mice exhibit hypoplastic tendon through the downregulation of tendon-related genes and MicroRNAs. Front Cell Dev Biol. 2022;10:898428.